259 related articles for article (PubMed ID: 20338043)
1. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial.
Bosello S; De Santis M; Lama G; Spanò C; Angelucci C; Tolusso B; Sica G; Ferraccioli G
Arthritis Res Ther; 2010; 12(2):R54. PubMed ID: 20338043
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Bosello SL; De Luca G; Rucco M; Berardi G; Falcione M; Danza FM; Pirronti T; Ferraccioli G
Semin Arthritis Rheum; 2015 Feb; 44(4):428-36. PubMed ID: 25300701
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
Lafyatis R; Kissin E; York M; Farina G; Viger K; Fritzler MJ; Merkel PA; Simms RW
Arthritis Rheum; 2009 Feb; 60(2):578-83. PubMed ID: 19180481
[TBL] [Abstract][Full Text] [Related]
4. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis.
van Laar JM
Arthritis Res Ther; 2010; 12(2):112. PubMed ID: 20441607
[TBL] [Abstract][Full Text] [Related]
6. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
7. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
Hasegawa M
J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
[TBL] [Abstract][Full Text] [Related]
8. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.
Hasegawa M; Hamaguchi Y; Yanaba K; Bouaziz JD; Uchida J; Fujimoto M; Matsushita T; Matsushita Y; Horikawa M; Komura K; Takehara K; Sato S; Tedder TF
Am J Pathol; 2006 Sep; 169(3):954-66. PubMed ID: 16936269
[TBL] [Abstract][Full Text] [Related]
9. B cells in systemic sclerosis: a possible target for therapy.
Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
13. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
14. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.
Bosello S; Angelucci C; Lama G; Alivernini S; Proietti G; Tolusso B; Sica G; Gremese E; Ferraccioli G
Arthritis Res Ther; 2018 Apr; 20(1):75. PubMed ID: 29669578
[TBL] [Abstract][Full Text] [Related]
15. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
[TBL] [Abstract][Full Text] [Related]
16. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance.
Matsushita T; Kobayashi T; Mizumaki K; Kano M; Sawada T; Tennichi M; Okamura A; Hamaguchi Y; Iwakura Y; Hasegawa M; Fujimoto M; Takehara K
Sci Adv; 2018 Jul; 4(7):eaas9944. PubMed ID: 30009261
[TBL] [Abstract][Full Text] [Related]
17. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
18. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
19. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 (rituximab) treatment improves atopic eczema.
Simon D; Hösli S; Kostylina G; Yawalkar N; Simon HU
J Allergy Clin Immunol; 2008 Jan; 121(1):122-8. PubMed ID: 18206507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
